Trials / Completed
CompletedNCT05237752
A Phase Ib/II Clinical Trial to Evaluate the Safety and Efficacy of LG00034053 in Patients With Knee OA
A Phase Ib/II, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of a Single Dose of LG00034053 Administered by Intra-articular Injection in Patients With Knee Osteoarthritis
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 74 (actual)
- Sponsor
- LG Chem · Industry
- Sex
- All
- Age
- 40 Years – 80 Years
- Healthy volunteers
- Accepted
Summary
This study is a multi-center, randomized, placebo-controlled, double-blind clinical study, consisting of Part 1 (Phase 1b) in a sequential, dose-escalating design and Part 2 (Phase 2) in a parallel design.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LG00034053 | a pan-caspase inhibitor, as a therapeutic agent of osteoarthritis |
Timeline
- Start date
- 2022-04-27
- Primary completion
- 2023-12-19
- Completion
- 2024-03-11
- First posted
- 2022-02-14
- Last updated
- 2024-05-03
Locations
2 sites across 2 countries: Australia, South Korea
Source: ClinicalTrials.gov record NCT05237752. Inclusion in this directory is not an endorsement.